These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 10858356)

  • 1. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model.
    Akins RL; Rybak MJ
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1925-9. PubMed ID: 10858356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Akins RL; Rybak MJ
    Antimicrob Agents Chemother; 2001 Feb; 45(2):454-9. PubMed ID: 11158740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR; Allen GP; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2991-8. PubMed ID: 11036011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
    LaPlante KL; Rybak MJ; Leuthner KD; Chin JN
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1298-303. PubMed ID: 16569844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model.
    Lee DG; Chun HS; Yim DS; Choi SM; Choi JH; Yoo JH; Shin WS; Kang MW
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3768-73. PubMed ID: 14638480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Tsuji BT; Rybak MJ
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2735-45. PubMed ID: 15980344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
    Marco F; de la Mària CG; Armero Y; Amat E; Soy D; Moreno A; del Río A; Almela M; Mestres CA; Gatell JM; Jiménez de Anta MT; Miró JM;
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2538-43. PubMed ID: 18426900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Cha R; Rybak MJ
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):539-46. PubMed ID: 14596973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
    Houlihan HH; Mercier RC; Rybak MJ
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2497-501. PubMed ID: 9371356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
    Fernandez J; Abbanat D; Shang W; He W; Amsler K; Hastings J; Queenan AM; Melton JL; Barron AM; Flamm RK; Lynch AS
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1476-84. PubMed ID: 22232278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Rose WE; Leonard SN; Rybak MJ
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3061-7. PubMed ID: 18591272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.
    Torrico M; Aguilar L; Sevillano D; Giménez MJ; Alou L; González N; Cafini F; Cleeland R; Prieto J
    Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of arbekacin alone and in combination with vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus.
    You I; Kariyama R; Zervos MJ; Kumon H; Chow JW
    Diagn Microbiol Infect Dis; 2000 Jan; 36(1):37-41. PubMed ID: 10744365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Huang V; Rybak MJ
    Antimicrob Agents Chemother; 2005 Jan; 49(1):302-8. PubMed ID: 15616309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
    DeRyke CA; Sutherland C; Zhang B; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates.
    Wootton M; MacGowan AP; Walsh TR
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4195-7. PubMed ID: 17043121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
    LaPlante KL; Rybak MJ
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus.
    Watanabe T; Ohashi K; Matsui K; Kubota T
    J Antimicrob Chemother; 1997 Apr; 39(4):471-6. PubMed ID: 9145819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
    da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
    BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.